Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 9/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.33 |
| ▸ | GPR6 | P46095 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2115728 | 0.92 | OPRK1 (0.38) | OPRK1GPR6NPSR1 | |
| SCHEMBL2113719 | 0.92 | CCNT1 (0.38) | OPRK1PRKD1 | |
| SCHEMBL2115676 | 0.88 | OPRK1 (0.37) | OPRK1 | |
| SCHEMBL2113546 | 0.88 | KCNH2 (0.37) | OPRK1 | |
| SCHEMBL2113549 | 0.88 | KCNH2 (0.37) | OPRK1 | |
| SCHEMBL2115362 | 0.88 | OPRK1 (0.34) | OPRK1KMT2APIK3CA | |
| SCHEMBL2115344 | 0.86 | OPRK1 (0.38) | OPRK1 | |
| SCHEMBL2115342 | 0.86 | OPRK1 (0.38) | OPRK1 | |
| SCHEMBL2114304 | 0.86 | MALT1 (0.39) | RXFP1PDE10AMALT1NPSR1PIK3CA | |
| SCHEMBL2114702 | 0.86 | P2RX3 (0.38) | OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | claimed |
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | OPRK1 305/4885RXFP1 4075/4885PDE10A 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.